118 related articles for article (PubMed ID: 38403951)
21. Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies.
Steffes VM; Murali MM; Park Y; Fletcher BJ; Ewert KK; Safinya CR
Biomaterials; 2017 Nov; 145():242-255. PubMed ID: 28889081
[TBL] [Abstract][Full Text] [Related]
22. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy.
Li C; Qiu Q; Gao X; Yan X; Fan C; Luo X; Liu X; Wang S; Lai X; Song Y; Deng Y
J Control Release; 2021 Sep; 337():393-406. PubMed ID: 34171446
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin.
Strieth S; Eichhorn ME; Werner A; Sauer B; Teifel M; Michaelis U; Berghaus A; Dellian M
Clin Cancer Res; 2008 Jul; 14(14):4603-11. PubMed ID: 18628475
[TBL] [Abstract][Full Text] [Related]
24. A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody-drug conjugates inspires robust tumor-specific immunological memory in solid tumors.
Sun W; Li Y; Sui D; Qi Z; Zhao X; Zhou W; Hu H; Liu X; Song Y; Deng Y
Biomater Sci; 2023 Apr; 11(8):2787-2808. PubMed ID: 36825722
[TBL] [Abstract][Full Text] [Related]
25. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes.
Jiménez-López J; Bravo-Caparrós I; Cabeza L; Nieto FR; Ortiz R; Perazzoli G; Fernández-Segura E; Cañizares FJ; Baeyens JM; Melguizo C; Prados J
Biomed Pharmacother; 2021 Jan; 133():111059. PubMed ID: 33378963
[TBL] [Abstract][Full Text] [Related]
27. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells.
Filion MC; Phillips NC
Biochim Biophys Acta; 1997 Oct; 1329(2):345-56. PubMed ID: 9371426
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronan Reduces Cationic Liposome-Induced Toxicity and Enhances the Antitumor Effect of Targeted Gene Delivery in Mice.
Qian Y; Liang X; Yang J; Zhao C; Nie W; Liu L; Yi T; Jiang Y; Geng J; Zhao X; Wei X
ACS Appl Mater Interfaces; 2018 Sep; 10(38):32006-32016. PubMed ID: 30156827
[TBL] [Abstract][Full Text] [Related]
29. Targeted Delivery of Arctigenin Using Sialic Acid Conjugate-Modified Liposomes for the Treatment of Breast Cancer.
Liu S; He Y; Feng M; Huang Y; Wu W; Wang J
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202860
[TBL] [Abstract][Full Text] [Related]
30. Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives.
Song Y; She Z; Huang Z; Wang S; Liu X; Zhang Q; Sun J; Di D; Deng Y
Drug Deliv Transl Res; 2022 Mar; 12(3):647-661. PubMed ID: 33928513
[TBL] [Abstract][Full Text] [Related]
31. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
Awada A; Bondarenko IN; Bonneterre J; Nowara E; Ferrero JM; Bakshi AV; Wilke C; Piccart M;
Ann Oncol; 2014 Apr; 25(4):824-831. PubMed ID: 24667715
[TBL] [Abstract][Full Text] [Related]
32. Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
Han B; Yang Y; Chen J; Tang H; Sun Y; Zhang Z; Wang Z; Li Y; Li Y; Luan X; Li Q; Ren Z; Zhou X; Cong D; Liu Z; Meng Q; Sun F; Pei J
Int J Nanomedicine; 2020; 15():553-571. PubMed ID: 32158208
[TBL] [Abstract][Full Text] [Related]
33. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex.
Hattori Y; Nakamura M; Takeuchi N; Tamaki K; Shimizu S; Yoshiike Y; Taguchi M; Ohno H; Ozaki KI; Onishi H
J Drug Target; 2019 Feb; 27(2):217-227. PubMed ID: 30024300
[TBL] [Abstract][Full Text] [Related]
34. Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells.
Dabbas S; Kaushik RR; Dandamudi S; Kuesters GM; Campbell RB
Endothelium; 2008; 15(4):189-201. PubMed ID: 18663622
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer.
Karpuz M; Silindir-Gunay M; Ozer AY; Ozturk SC; Yanik H; Tuncel M; Aydin C; Esendagli G
Eur J Pharm Sci; 2021 Jan; 156():105576. PubMed ID: 32987115
[TBL] [Abstract][Full Text] [Related]
37. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.
Biswas S; Dodwadkar NS; Deshpande PP; Torchilin VP
J Control Release; 2012 May; 159(3):393-402. PubMed ID: 22286008
[TBL] [Abstract][Full Text] [Related]
38. Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery.
Huang M; Pu Y; Peng Y; Fu Q; Guo L; Wu Y; Zheng Y
Bioorg Med Chem Lett; 2020 Jun; 30(12):127151. PubMed ID: 32317211
[TBL] [Abstract][Full Text] [Related]
39. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes.
Gross N; Ranjbar M; Evers C; Hua J; Martin G; Schulze B; Michaelis U; Hansen LL; Agostini HT
Mol Vis; 2013; 19():54-61. PubMed ID: 23335851
[TBL] [Abstract][Full Text] [Related]
40. Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer.
Zhang L; Wang Y; Xia T; Yu Q; Zhang Q; Yang Y; Cun X; Lu L; Gao H; Zhang Z; He Q
Drug Deliv; 2016 Oct; 23(8):2970-2979. PubMed ID: 26758229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
